Journal: Journal of Cancer

Article Title: Preliminary study on SPECT/CT imaging of pancreatic cancer xenografts by targeting integrin α5 in pancreatic stellate cells

doi: 10.7150/jca.51190

Figure Lengend Snippet: Western blotting assay (A) and cell immunofluorescence staining (B) of ITGA5 expression in PSCs without or with SW1990-CM treatment. * P < 0.05 , n = 3.

Article Snippet: The human pancreatic cancer SW1990 cells and PSCs were obtained from Tongpai (Shanghai) Biotechnology Co., LTD. Anti-ITGA5 antibody and FITC-labeled secondary antibody were purchased from Beijing Bioss Biotechnology Co., LTD. DMEM and fetal bovine serum (FBS) were purchased from Gibco Life Technology Co., LTD.

Techniques: Western Blot, Immunofluorescence, Staining, Expressing

Journal: Journal of Cancer

Article Title: Preliminary study on SPECT/CT imaging of pancreatic cancer xenografts by targeting integrin α5 in pancreatic stellate cells

doi: 10.7150/jca.51190

Figure Lengend Snippet: Representative 125 I-AV3 SPECT/CT imaging at 4 h (A), corresponding SPECT/CT imaging with a blocking dose of AV3 (B) and ITGA5 IHC staining (C) of pancreatic cancer xenografts in nude mice. The xenografts tumors in nude mice were established using SW1990 cells injection alone in the left lower limb (indicated by asterisk) or SW1990 + PSCs co-injection in the right lower limb (indicated by arrow). Pancreatic cancer-bearing nude mice were injected about 1 mCi 125 I-AV3 from tail vein before the imaging study. Repeated experiments showed similar results.

Article Snippet: The human pancreatic cancer SW1990 cells and PSCs were obtained from Tongpai (Shanghai) Biotechnology Co., LTD. Anti-ITGA5 antibody and FITC-labeled secondary antibody were purchased from Beijing Bioss Biotechnology Co., LTD. DMEM and fetal bovine serum (FBS) were purchased from Gibco Life Technology Co., LTD.

Techniques: Single Photon Emission Computed Tomography, Imaging, Blocking Assay, Immunohistochemistry, Injection

Journal: Frontiers in Immunology

Article Title: Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

doi: 10.3389/fimmu.2023.1168444

Figure Lengend Snippet: Pre-clinical evaluation of the three selected lead BiXAb™ 3Patri-2Trastu-Fc, 3Patri-1Matu-Fc, and 3Patri-1Cetu-Fc. (A) Tumor growth (left) and survival (middle) of BiXAb™-treated mice xenografted with Sw1990 and PDX P2846 PDAC cells. The percentage of tumor growth inhibition (TGI) at treatment end, and the 50% survival benefit (days) are indicated in the right panel. (B) Immunohistochemistry analysis of BiXAb™ penetration in Sw1990 cell xenografts. BiXAb™ were detected using peroxidase-conjugated anti-human Fc. IRR BiXAb™, BiXAb™ targeting HLA-DR and CD5 (negative control). NaCl was used as negative control. (C) Tumor penetration of 3Patri-1Cetu-Fc evaluated in whole tumor slices at lower magnification. The external (Ext) and internal (Int) parts of the tumor slice are indicated.

Article Snippet: Sw1990 cells (3x10 6 cells per mouse) or the PDX P2846 at passage 8 (P8) since surgery (125 mm 3 tumor piece per mouse) were injected subcutaneously in the right flank, or transplanted intrascapularly in the brown fat, respectively, of 6 week/old female Swiss nude (Crl : NU(Ico)-Foxn1nu) mice from Charles River (Wilmington, MA).

Techniques: Inhibition, Immunohistochemistry, Negative Control

Journal: Frontiers in Immunology

Article Title: Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

doi: 10.3389/fimmu.2023.1168444

Figure Lengend Snippet: NK cell engagement and receptor expression. (A) Immunophenotyping by flow cytometry of NK cells in Sw1990 cell xenografts resected from BiXAb™-treated mice. Dissociated cells were labeled with human CD49-, NKp46-, IFNγ- and CD107-specific antibodies. (B) Immunofluorescence analysis of EGFR expression by immunofluorescence in 3Patri-1Cetu-Fc-, IRR BiXAb™- and NaCl-treated Sw1990 cell xenografts. (C) Western blot analysis of ErbB receptor expression in Sw1990 cell xenografts from mice treated with NaCl, 3Patri-2Trastu-Fc, 3Patri-1Matu-Fc, or 3Patri-1Cetu-Fc. Tubulin was used as loading control. (D) Western blots were quantified using the LI-COR Odyssey imaging system. ErbB expression level was normalized to tubulin expression level. Each experiment was performed using three Sw1990 cell xenografted mice. IRR BiXAb™, negative control. Data are the mean ± SEM. P-values: p <0.05 (*), p <0.01 (**), p <0.001 (***), ns (not significant).

Article Snippet: Sw1990 cells (3x10 6 cells per mouse) or the PDX P2846 at passage 8 (P8) since surgery (125 mm 3 tumor piece per mouse) were injected subcutaneously in the right flank, or transplanted intrascapularly in the brown fat, respectively, of 6 week/old female Swiss nude (Crl : NU(Ico)-Foxn1nu) mice from Charles River (Wilmington, MA).

Techniques: Expressing, Flow Cytometry, Labeling, Immunofluorescence, Western Blot, Control, Imaging, Negative Control

Journal: Frontiers in Immunology

Article Title: Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

doi: 10.3389/fimmu.2023.1168444

Figure Lengend Snippet: In vivo effects of the best-in-class BiXAb™ 3Patri-1Cetu-Fc versus 2MAbs and 1MAbs. Tumor growth (left panel) and survival (middle panel) of mice xenografted with Sw1990 and PDX P2846 PDAC cells treated with the indicated antibodies (n=10 mice/group). The percentage of tumor growth inhibition (TGI), and the 50% survival benefit (days) are indicated in the right panel. The BiXAb™ 3Patri-1Cetu-Fc was used at Fab equimolarity (8.5 mg/kg) or Fc equimolarity (17 mg/kg).

Article Snippet: Sw1990 cells (3x10 6 cells per mouse) or the PDX P2846 at passage 8 (P8) since surgery (125 mm 3 tumor piece per mouse) were injected subcutaneously in the right flank, or transplanted intrascapularly in the brown fat, respectively, of 6 week/old female Swiss nude (Crl : NU(Ico)-Foxn1nu) mice from Charles River (Wilmington, MA).

Techniques: In Vivo, Inhibition

Journal: Frontiers in Immunology

Article Title: Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

doi: 10.3389/fimmu.2023.1168444

Figure Lengend Snippet: Characterization of 3Patri-1Cetu-Fc tumor penetration, and its effects on tumor angiogenesis and proliferation in mice xenografted with Sw1990 cells. (A) Immunohistochemistry analysis of the penetration of the BiXAb™ 3Patri-1Cetu-Fc, the 2MAbs 3Patri+1Cetu, and 3Patri and 1Cetu in tumor xenograft sections (x20 magnification; left panels). Antibodies were detected with a peroxidase-conjugated anti-human Fc. Human Fc-positive cells (right panel) were quantified in the whole tumor section using the QuPath software. Immunohistochemistry analysis (x20 magnification; left panel) of CD31 angiogenesis (B) and Ki67 proliferation (C) in Sw1990 cell xenografts. CD31+ microvessel density was estimated as the mean value in ten histological fields using the Image J software. The percentage of Ki-67+ cells in tumors was quantified in the whole tumor section using the Qupath software. IRR BiXAb™, negative control BiXAb™. Data are the mean ± SEM (n=5 mice/group). P-values: p <0.05 (*), p <0.01 (**), p <0.001 (***), ns (not significant). Immunohistochemistry analysis of P2846 xenografts is in Supplementary Figure 6 .

Article Snippet: Sw1990 cells (3x10 6 cells per mouse) or the PDX P2846 at passage 8 (P8) since surgery (125 mm 3 tumor piece per mouse) were injected subcutaneously in the right flank, or transplanted intrascapularly in the brown fat, respectively, of 6 week/old female Swiss nude (Crl : NU(Ico)-Foxn1nu) mice from Charles River (Wilmington, MA).

Techniques: Immunohistochemistry, Software, Negative Control

Journal: Frontiers in Pharmacology

Article Title: Phytopharmacology and Clinical Updates of Berberis Species Against Diabetes and Other Metabolic Diseases

doi: 10.3389/fphar.2020.00041

Figure Lengend Snippet: In vitro activity of extracts and/or isolated compounds from Berberis species against diabetes and metabolic diseases.

Article Snippet: Berberine (BBR) , CEM, HCT-116, HepG2.2.15, SW1990, HT1080 and 293T cell lines , ↑gene expression of the insulin receptor , ( ) .

Techniques: In Vitro, Activity Assay, Isolation, Binding Assay, Activation Assay, Cell Culture, Expressing, Small Interfering RNA, Blocking Assay, Gene Expression, Inhibition, Translocation Assay, Phospho-proteomics, Modification

Journal: PLoS ONE

Article Title: Inhibition of prenylated KRAS in a lipid environment

doi: 10.1371/journal.pone.0174706

Figure Lengend Snippet: Dose-response data for all compounds from on SW1990 cells (A) and A375 cells (B), assessing impact on pAKT and pERK, together with their total protein controls and a GAPDH control.

Article Snippet: SW1990 and A375 cell lines were obtained from the Broad-Novartis Cancer Cell Line Encyclopedia collection and cultured in DMEM or RPMI supplemented with 10% FBS.

Techniques: Control